San Rocco Therapeutics v. Bluebird Bio: Gene Therapy Patent Dispute Ends in Summary Judgment
San Rocco Therapeutics alleged that Bluebird Bio’s ZYNTEGLO and LENTIGLOBIN betibeglogene autotemcel (beti-cel) products, built on the BB305 lentiviral vector, infringed four gene therapy patents. After 1,303 days of litigation in Delaware, Judge Andrews granted summary judgment entirely in Bluebird’s favour — ending the case without trial.
Four gene therapy patents, one summary judgment: Bluebird prevails in Delaware
Filed in October 2021 in the District of Delaware, this infringement action saw San Rocco Therapeutics assert four patents — US7541179, US9783822, US8058061, and US60302852 — against Bluebird Bio’s commercially significant ZYNTEGLO and LENTIGLOBIN beti-cel products and the underlying BB305 lentiviral vector. Third Rock Ventures, a prominent life-sciences venture fund closely associated with Bluebird’s founding, was named as a co-defendant, suggesting San Rocco sought liability across both the commercial entity and its financial backer.
The case closed on 16 May 2025 when Judge Richard G. Andrews granted Bluebird’s Motion for Summary Judgment (D.I. 179) in full. A summary judgment outcome on the merits means the court determined that no genuine dispute of material fact existed sufficient to warrant a jury trial — a high bar for the movant in patent litigation. The accompanying Memorandum Opinion will govern the detailed legal reasoning, but the result leaves San Rocco with no surviving claim in this proceeding.
At 1,303 days, the case ran for nearly three and a half years before resolution — consistent with the complexity of gene therapy patent disputes, which typically involve intricate claim construction battles over molecular biology terminology. What remains unknown from the public record at this stage is precisely which invalidity or non-infringement grounds proved dispositive: the Memorandum Opinion will clarify whether the court found the BB305 vector outside the claim scope, the asserted claims invalid, or both. Either outcome carries significant IP implications for the emerging gene therapy sector.
Filing to Judgment on the merits for Defendant in 1303 days
1,303 days — above the median for Delaware District Court patent cases, reflecting complex gene therapy claim construction
Summary judgment for defendants: what the ruling means for both parties
Summary judgment: the court found no triable fact dispute
Summary judgment under Fed. R. Civ. P. 56 is granted only when no genuine dispute of material fact exists and the movant is entitled to judgment as a matter of law. In patent cases, this typically means the court resolved infringement or validity as a pure legal question — often following claim construction. A grant of summary judgment for the defendant is a complete, merits-based victory: it extinguishes the plaintiff’s claims with full preclusive effect.
Merits-based defendant victorySan Rocco’s claims extinguished — re-litigation barred by res judicata
A summary judgment on the merits operates as a final judgment. San Rocco Therapeutics cannot re-assert the same claims against Bluebird Bio on these four patents in a new district court action — res judicata applies. Any further challenge would require an appeal to the Federal Circuit. The ruling also signals that the asserted patents may face continued scrutiny if San Rocco pursues enforcement against other gene therapy actors using comparable lentiviral vector technology.
Claims barred — appeal only routeBluebird’s beti-cel products cleared on all asserted patents
Bluebird Bio and Third Rock Ventures secured a complete merits victory without trial. ZYNTEGLO and LENTIGLOBIN beti-cel, along with the BB305 lentiviral vector, are no longer subject to these patent claims in this jurisdiction. The ruling strengthens Bluebird’s commercial position in the beta-thalassemia and sickle cell gene therapy market, removing a significant litigation overhang at a critical commercialisation stage for both products.
BB305 vector commercially clearedGene therapy IP enforcement: a cautionary signal for licensing entities
This outcome suggests that lentiviral vector patents, when asserted against well-resourced gene therapy developers with strong technical records, face a meaningful summary judgment risk — particularly where claim scope and vector design specifics can be resolved as a matter of law. For sector participants, the ruling may reduce licensing leverage for similar foundational gene therapy IP, and reinforces the importance of robust claim construction positions before asserting broad vector patents against approved products.
Licensing leverage risk for vector IPFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | San Rocco Therapeutics, LLC | Company | Gene therapy IP licensing entity — holder of lentiviral vector patents US7541179, US9783822, US8058061, US60302852Search in Eureka ↗ |
| Defendant | Bluebird Bio, Inc. | Company | Bluebird Bio, Inc. — rare disease gene therapy company, developer of ZYNTEGLO and LENTIGLOBIN beti-celSearch in Eureka ↗ |
| Co-Defendant | Third Rock Ventures, LLC | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexandra Cavazos | Attorney | Counsel for San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Anne Shea Gaza | Attorney | Counsel for San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Crystal Law | Attorney | Counsel for San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Daniel G. Mackrides | Attorney | Counsel for San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Plaintiff counsel | David Forrest | Attorney | Counsel for San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Howard S. Suh | Attorney | Counsel for San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Plaintiff counsel | James H. McConnell | Attorney | Counsel for San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Joe G. Chen | Attorney | Counsel for San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Lauren B. Sabol | Attorney | Counsel for San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Lenore Horton | Attorney | Counsel for San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Lukas Toft | Attorney | Counsel for San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Mary Jean Kim | Attorney | Counsel for San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Natalie I. Uhlemann | Attorney | Counsel for San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Samantha G. Wilson | Attorney | Counsel for San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Wanda D. French-Brown | Attorney | Counsel for San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Young Conaway Stargatt & Taylor, LLP | Law Firm | Representing San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Defendant counsel | Eric W. Dittmann | Attorney | Counsel for Bluebird Bio, Inc.Search in Eureka ↗ |
| Defendant counsel | Jack B. Blumenfeld | Attorney | Counsel for Bluebird Bio, Inc.Search in Eureka ↗ |
| Defendant counsel | Jeremy A. Tigan | Attorney | Counsel for Bluebird Bio, Inc.Search in Eureka ↗ |
| Defendant counsel | Joshua M. Bennett | Attorney | Counsel for Bluebird Bio, Inc.Search in Eureka ↗ |
| Defendant counsel | Krystina L. Ho | Attorney | Counsel for Bluebird Bio, Inc.Search in Eureka ↗ |
| Defendant counsel | Max H. Yusem | Attorney | Counsel for Bluebird Bio, Inc.Search in Eureka ↗ |
| Defendant counsel | Naveen Modi | Attorney | Counsel for Bluebird Bio, Inc.Search in Eureka ↗ |
| Defendant law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Bluebird Bio, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s order granting Defendants’ Motion for Summary Judgment (D.I. 179) in full, with reference to an accompanying Memorandum Opinion, reflects a comprehensive merits ruling rather than a procedural disposal. The framing — ‘for the reasons stated in the accompanying Memorandum Opinion’ — indicates that substantive legal analysis, most likely on infringement scope, invalidity, or both, underlies the result. For San Rocco, this is the most adverse outcome short of a jury verdict: all claims are extinguished with preclusive effect, and the detailed reasoning in the Memorandum Opinion will govern any Federal Circuit appeal strategy.
US7541179, US9783822, US8058061 & US60302852 — Lentiviral vector gene therapy patents
The four asserted patents — US7541179, US9783822, US8058061, and US60302852 — appear to cover foundational lentiviral vector technology used to deliver therapeutic genes into patient cells. Lentiviral vectors, derived from retroviruses, are the predominant delivery vehicle for ex vivo gene therapies targeting haematopoietic stem cells. The patents span application numbers suggesting a priority chain stretching back to at least the early 2000s, with US60302852 being a provisional application that may anchor the priority date for the family. The BB305 vector at the centre of this dispute is the specific lentiviral construct that delivers a functional beta-globin gene in Bluebird Bio’s beti-cel therapies.
Lentiviral vector patents occupy strategically critical real estate in the gene therapy IP landscape: they sit at the platform level, meaning a single patent family can potentially reach multiple therapeutic programmes across different indications. Bluebird’s beti-cel products — approved for beta-thalassemia (ZYNTEGLO) — represent one of the first commercially approved gene therapies in the US, making them high-value enforcement targets. A successful assertion against beti-cel could have set licensing precedent across the broader haematopoietic gene therapy sector. The summary judgment outcome narrows that enforcement pathway considerably for this patent family.
Should your gene therapy programme run an FTO against these lentiviral vector patents?
Any R&D team developing ex vivo gene therapies using lentiviral vectors for haematopoietic stem cell modification should treat US7541179, US9783822, and US8058061 as active FTO considerations, notwithstanding Bluebird’s summary judgment win. That victory is defendant-specific and fact-specific — it does not invalidate the patents or bind other potential infringers. Companies developing BB305-adjacent vector designs, globin gene therapy programmes, or novel lentiviral constructs for sickle cell disease or thalassemia face independent FTO exposure and should conduct claim-by-claim analysis against their specific vector architecture.
PatSnap Eureka’s FTO Search Agent can map your lentiviral vector design against the full claim scope of this patent family, identify prosecution history estoppel arguments, surface relevant prior art that may support invalidity positions, and flag continuation applications that may still be pending. Given the multi-patent assertion strategy deployed by San Rocco, monitoring the family for continuation filings and reissue applications is particularly important for gene therapy developers seeking commercial freedom ahead of regulatory approval.
Run a freedom-to-operate analysis on US7541179 to assess your product’s exposure
Run FTO in Eureka →Related gene therapy patent litigation in Delaware District Court
Explore comparable lentiviral vector and gene therapy patent infringement cases litigated before the Delaware District Court, including summary judgment outcomes and claim construction rulings.
What this case signals for the gene therapy IP landscape
A full summary judgment defence win over lentiviral vector patents sets a precedent-relevant data point for gene therapy IP enforcement strategy.
Approved gene therapy products attract high-quality patent defences
Bluebird Bio’s ZYNTEGLO and LENTIGLOBIN beti-cel are FDA-approved products with extensive regulatory and clinical documentation. That technical record typically enables defendants to build granular non-infringement arguments at the claim element level — reducing the likelihood that factual disputes survive summary judgment in vector patent cases.
Naming a VC firm as co-defendant creates strategic and reputational risk
San Rocco’s inclusion of Third Rock Ventures as a defendant is notable. Asserting liability against a venture fund alongside the operating company is an aggressive tactic that can complicate settlement dynamics and signal a damages theory extending beyond product revenue to investment returns. The strategy did not survive summary judgment here, but it remains a tactic to monitor in pharma IP litigation.
San v Bluebird — key questions answered
The Delaware District Court granted summary judgment entirely in favour of defendants Bluebird Bio and Third Rock Ventures on 16 May 2025. Judge Richard G. Andrews issued a Memorandum Opinion accompanying the order. The ruling is a merits-based final judgment, extinguishing San Rocco’s infringement claims on all four asserted patents with preclusive effect.
San Rocco asserted four patents: US7541179, US9783822, US8058061, and provisional application US60302852. These appear to cover lentiviral vector technology relevant to the BB305 vector used in Bluebird’s ZYNTEGLO and LENTIGLOBIN betibeglogene autotemcel (beti-cel) gene therapy products approved for beta-thalassemia treatment.
Third Rock Ventures, a life-sciences venture capital firm closely associated with Bluebird Bio’s founding, was named as a co-defendant — a relatively unusual step. This suggests San Rocco may have pursued a damages or liability theory extending beyond Bluebird’s commercial product revenues to the investment entity level. The strategy did not survive summary judgment, but the public record does not specify on what grounds Third Rock’s liability was rejected.
Not necessarily. A summary judgment win for a defendant can rest on non-infringement grounds (the accused product falls outside the claim scope), invalidity grounds, or both. Until the Memorandum Opinion is reviewed in detail, the precise basis is not confirmed. Critically, the patents remain in force unless found invalid, and San Rocco could potentially assert them against other parties whose products differ from the BB305 vector.
Yes. A final judgment from the Delaware District Court is appealable to the United States Court of Appeals for the Federal Circuit, which has exclusive jurisdiction over patent appeals. San Rocco would need to identify reversible legal error in Judge Andrews’s claim construction or summary judgment analysis. The detailed Memorandum Opinion will be the primary document governing any Federal Circuit appeal strategy.
PatSnap Eureka searches patents and litigation data to answer instantly.